Transformative Diagnostics



Next-Generation Therapies & Vaccines

Addressing large, unmet global markets with innovative proprietary products More »


Worldwide Production & Distribution

Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »


Strategic Investments

Identifying early-stage companies with potential to increase value for shareholders More »

Chairman’s Message

OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors and I would like to review several highlights.



 OPKO Completes Acquisition of Bio-Reference Laboratories.



OPKO Letter to Shareholders»

News & Events

more news »

Vanderbilt University School of Medicine and OPKO Health Collaborate on Genomics more »

OPKO to Host Symposium to Present Clinical Data on its Long-acting Human Growth Hormone at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology more »

OPKO Presents Clinical Data on its Long-acting Human Growth Hormone (hGH-CTP) in Two Oral Presentations at the 54th Annual Meeting of the European Society for Pediatric Endocrinology (ESPE) more »


read more »

OPKO Health is an opportunistic research and development company that targets large, high-growth markets.



Former shareholders of Bio-Reference Laboratories, Inc. that have questions related to the exchange of BRLI shares to OPK shares, please contact our exchange agent, American Stock Transfer & Trust Company, LLC, toll free at (877) 248-6417 or (718) 921-8317.